UNSPSC 51161542: Furafylline

This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C12H12N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C2087G0XX3, chemically known as 3-furfuryl-1,8-dimethylxanthine but generally known as furafylline, which bears US NIH Compound Identifier 3433. European Medicines Agency schedules Furafylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07829MIG.

UNSPSC 51161542 Furafylline is a Commodity code representing generic pharmaceutical products and over-the-counter formulations procured by state and local health agencies, purchasing cooperatives, and institutional healthcare facilities. State and local governments acquire these medications through multi-source pharmaceutical contracts that establish pricing and supply relationships with manufacturers and authorized wholesalers, then distribute stock across state departments, county health systems, municipal clinics, and other public healthcare operations. The scope reflects demand for standardized generic drugs and OTC products in public healthcare settings, with procurement structured around National Drug Codes, specific dosage forms, packaging configurations, and compliance certifications including current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance. Bidders must maintain contractual relationships with authorized pharmaceutical wholesalers, establish competitive pricing structures (flat price, net price, or WAC-minus formats), and carry substantial insurance coverage including $5 million commercial general liability and $2 million network security and privacy liability per occurrence.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed to participating state and local facilities in Minnesota and Oregon. The solicitation (S1070000015802) seeks manufacturers to supply comprehensive product portfolios with detailed specifications and pricing through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with proposals due March 26, 2026. The contract term is two years for new responders with optional MMCAP extensions, while incumbent vendors' agreements run through June 30, 2028. Evaluation weighs price competitiveness at 75 percent, fixed pricing and compliance factors at 20 percent combined, and EDI capability and administrative fee agreement at 10 percent combined. All awarded products must be available in the marketplace by May 15, 2026, effective July 1, 2026. Performance penalties of $200 to $1,500 per violation apply for late reporting, missed onboarding, or improper class-of-trade denials, and vendors pay a 3 percent administrative fee on all contract purchases.